Accord Healthcare introduces Pemetrexed Lyo. Injection to range of chemotherapy drugs
30 May 2022 -

Accord Healthcare, Inc., a US-based generic pharmaceutical company, announced on Friday that it has added Pemetrexed Lyo. Injection to its range of chemotherapy drugs.

The product is formulated as a sterile lyophilised (freeze-dried) powder to be reconstituted for intravenous infusion. It is therapeutically equivalent to Eli Lilly and Company's ALIMTA and approved for the treatment of Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma (MPM), a cancer of the inside lining of the chest cavity. It is available in vials of 100mg, 500mg, and 1000mg strengths and is presently available to ship.

Accord CEO Jeff Hampton, said, 'Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications. We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future.'